Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease
Autore:
van de Vijver, DAMC; Stricker, BHC; Breteler, MMB; Roos, RAC; Porsius, AJ; de Boer, A;
Indirizzi:
Univ Utrecht, Dept Pharmacoepidemiol & Pharmacotherapy, NL-3508 TB Utrecht, Netherlands Univ Utrecht Utrecht Netherlands NL-3508 TB 3508 TB Utrecht, Netherlands Erasmus Univ, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands Erasmus Univ Rotterdam Netherlands NL-3000 DR DR Rotterdam, Netherlands Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands Leiden Univ Leiden Netherlands ed Ctr, Dept Neurol, Leiden, Netherlands
Titolo Testata:
PHARMACY WORLD & SCIENCE
fascicolo: 4, volume: 23, anno: 2001,
pagine: 148 - 152
SICI:
0928-1231(2001)23:4<148:EOADIP>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
PREVALENCE; EPIDEMIOLOGY; ROTTERDAM;
Keywords:
antiparkinsonian drugs; elderly; Parkinson's disease; pharmacoepidemiology; pharmacy records;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: van de Vijver, DAMC Univ Utrecht, Dept Pharmacoepidemiol & Pharmacotherapy, POB 80082, NL-3508TB Utrecht, Netherlands Univ Utrecht POB 80082 UtrechtNetherlands NL-3508 TB
Citazione:
D.A.M.C. van de Vijver et al., "Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease", PHARM WORLD, 23(4), 2001, pp. 148-152

Abstract

Aim: The aim of this study was to determine whether use of antiparkinsonian drugs in pharmacy records can be used as a marker for patients with Parkinson's disease (PD). Method: Data were obtained from the Rotterdam Study, a community-based prospective cohort study among people aged 55 years or older who were all screened for PD. For 5510 persons, of whom 74 had PD, pharmacy records were available. Stepwise logistic regression analysis was used to evaluate whether age, sex and use of the antiparkinsonian drugs amantadine, anticholinergics, dopamine agonists, levodopa and selegiline, were predictive variables forPD. For each individual a probability for having PD was calculated. Sensitivity, specificity and positive predictive value (PPV) were calculated at different cut-off values based on calculated probabilities. Results: More than 90% of the users of levodopa, bromocriptine, selegiline, and users of at least two different antiparkinsonian drugs had PD. Age, use of amantadine, anticholinergics, bromocriptine, levodopa, and selegilinewere predictive variables for PD. After application of different cut-off values, sensitivity was at most 66.2%, and specificity was at least 99.8%. APPV of higher than 90% was obtained at higher probabilities. Conclusion: Based on the high PPV of our predictive model, antiparkinsonian drugs can be used as a reliable marker for PD in pharmacy records. Because sensitivity is low, pharmacy records cannot be used to estimate prevalence of PD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:48:36